ELI LILLY WKN: 858560 ISIN: US5324571083 Kürzel: LLY Forum: Aktien Thema: Hauptdiskussion

Na bitte was will man mehr 😊

$LLY reported good earnings results today with a double beat: ✅Revenue: $13.53B vs. $13.43B expected (+45% Y/Y) ✅EPS: $5.32 vs. $5.08 expected (+102% Y/Y) ✅ GLP-1 drugs, Mounjaro and Zepbound, are rapidly capturing market share in the booming obesity and diabetes treatment sector. ✅A strong pipeline in Alzheimer’s, oncology, and autoimmune treatments. The company’s Alzheimer’s drug, donanemab, is awaiting FDA approval and could be a multi-billion-dollar opportunity. ✅Revenue and earnings have soared, with over 40% year-over-year growth fueled by GLP-1 drugs. ❌ $NVO, the maker of Ozempic and Wegovy, is a major competitor, and potential new entrants could pressure Eli Lilly’s pricing power and growth. ❌Trades at a premium valuation, with a P/E ratio above 70. Any slowdown in GLP-1 sales or negative trial results could lead to sharp stock declines as expectations are sky-high. #LLY #StockMarket #stocks #stockmarketcrash #Investments #earnings https://x.com/Investing_Table/status/1887469472610492562?t=lHFUp2pxN5B9OYP1UBoxaQ&s=19

ELI LILLY $LLY JUST REPORTED EARNINGS EPS of $5.32 beating expectations of $5.06 Revenue of $13.53B beating expectations of $13.45B

💩das war jetzt gar nicht auf meinem Radar... sonst hätte ich wahrscheinlich 2st nachgekauft 🤦

Hier wird es bald abgehen

https://www.investing.com/news/analyst-ratings/bernstein-reiterates-eli-lilly-stock-outperform-with-1100-target-93CH-3853189

https://de.investing.com/news/stock-market-news/eli-lilly-eps-ubertrifft-schatzungen--um-002---umsatz-schlechter-als-erwartet-2865265

Finde die Zahlen sind sehr gut und der Ausblick passt auch

Seht auf der Lilly Website

Zahlen sind draußen

Frag ich mich auch

Oder was ist da los

Sind die zahlen draußen

Wegovy sales were up 100% Q on Q according to NVO's report, should be nice for LLY

Novo Zahlen waren ziemlich gut eig

14:30 uhr